Skip to main content
Top
Published in: Journal of Neuro-Oncology 3/2013

01-07-2013 | Clinical Study

Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma

Authors: Shengjun Wang, Weidong Yang, Jinglan Deng, Jianning Zhang, Fucheng Ma, Jing Wang

Published in: Journal of Neuro-Oncology | Issue 3/2013

Login to get access

Abstract

The aim of this study was to explore the association of 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy (SRS) with the pathological grading and expression of somatostatin receptor 2 (SSTR2) for meningioma, and to define possible roles of SRS in the pathological grading of meningioma. Thirty patients with meningiomas diagnosed by MRI and treated with 99mTc-HYNIC-octreotide SPECT/CT SRS. Meningioma tissues were obtained from analyzing pathological grading and measuring the expression of SSTR2 with immunohistochemical staining. The meningioma side (T) to the contralateral side (NT) ratios (T/TN) of radioactive counts were calculated to investigate their association with the pathological grading of meningioma and the expression of SSTR2. All 30 cases showed high meningioma radioactivity accumulation using SRS with a sensitivity of 100 %, while CT scans only detected 25 cases with a sensitivity of 83 %. Twenty cases with grade I meningioma had a T/NT ratio of 3.80 ± 1.67, which was significantly lower than the other 10 cases (9.57 ± 3.78) with a grade II meningioma (P < 0.01). All meningiomas expressed SSTR2 as detected by immunohistochemical staining, and the T/NT ratio was positively associated with the pathological grading of meningioma and the expression of SSTR2 (with r of 0.784 and 0.805, respectively). 99mTc-HYNIC-octreotide SPECT/CT SRS is a sensitive technique for detecting meningioma, and the T/NT ratio of the SRS data closely correlates with the pathological grade of meningioma and the expression of SSTR2.
Literature
1.
go back to reference Black P (1997) Meningiomas. In: Black P, Loeffler JS (eds) Cancer of the nervous systems. Blackwell Science, Oxford, pp 349–362 Black P (1997) Meningiomas. In: Black P, Loeffler JS (eds) Cancer of the nervous systems. Blackwell Science, Oxford, pp 349–362
2.
go back to reference Jääskeläinen J, Haltia M, Servo A (1986) A typical and anaplastic meningiomas: radiology, surgery, radiotherapy and outcome. Surg Neurol 25:233–242PubMedCrossRef Jääskeläinen J, Haltia M, Servo A (1986) A typical and anaplastic meningiomas: radiology, surgery, radiotherapy and outcome. Surg Neurol 25:233–242PubMedCrossRef
3.
go back to reference Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neuro-Oncol 70:183–202CrossRef Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neuro-Oncol 70:183–202CrossRef
4.
go back to reference Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A et al (2006) Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 65:222–227PubMedCrossRef Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A et al (2006) Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 65:222–227PubMedCrossRef
5.
go back to reference Dutour A, Kumar U, Panetta R, Quafik L, Fina F, Sasi R et al (1998) Expression of somatostain receptor subtypes in human brain tumors. Int J Cancer 76:620–627PubMedCrossRef Dutour A, Kumar U, Panetta R, Quafik L, Fina F, Sasi R et al (1998) Expression of somatostain receptor subtypes in human brain tumors. Int J Cancer 76:620–627PubMedCrossRef
6.
go back to reference Durd A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Schulz S et al (2008) Expression of c-myc, neurofibromatosis type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol 27:334–345 Durd A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Schulz S et al (2008) Expression of c-myc, neurofibromatosis type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol 27:334–345
7.
go back to reference Arena S, Barbieri F, Thaellungi S, Pirani P, Corsaro A, Villa V et al (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neuro-Oncol 66:155–166CrossRef Arena S, Barbieri F, Thaellungi S, Pirani P, Corsaro A, Villa V et al (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neuro-Oncol 66:155–166CrossRef
8.
go back to reference Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N et al (1998) Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25:675–686PubMedCrossRef Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N et al (1998) Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25:675–686PubMedCrossRef
9.
go back to reference Duet M, Sauvaget E, Pételle B, Rizzo N, Guichard JP, Wassef M et al (2003) Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 44:1767–1774PubMed Duet M, Sauvaget E, Pételle B, Rizzo N, Guichard JP, Wassef M et al (2003) Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 44:1767–1774PubMed
10.
go back to reference Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J et al (2005) Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 46:763–769PubMed Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J et al (2005) Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 46:763–769PubMed
11.
go back to reference Haldemann AR, Rosier H, Barth A, Waser B, Geiger L, Godoy N et al (1995) Somatostatin receptor scintigraphy in central nervous system tumors: role of blood–brain barrier permeability. J Nucl Med 36:403–410PubMed Haldemann AR, Rosier H, Barth A, Waser B, Geiger L, Godoy N et al (1995) Somatostatin receptor scintigraphy in central nervous system tumors: role of blood–brain barrier permeability. J Nucl Med 36:403–410PubMed
12.
go back to reference Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172–1182PubMedCrossRef Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172–1182PubMedCrossRef
13.
go back to reference Miederer M, Seidl S, Buck A, Scheidhauer K, Wester H-J, Schwaiger M et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48–52PubMedCrossRef Miederer M, Seidl S, Buck A, Scheidhauer K, Wester H-J, Schwaiger M et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48–52PubMedCrossRef
14.
go back to reference Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ (2000) 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumor: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 41:1114–1119PubMed Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ (2000) 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumor: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 41:1114–1119PubMed
15.
go back to reference Nicolato A, Giorgetti P, Foroni R, Grigolato D, Pasquin IP, Zuffante M et al (2005) Gamma knife radiosurgery in skull base meningiomas: a possible relationship between somatostatin receptor decrease and early neurological improvement without tumour shrinkage at short-term imaging follow-up. Acta Neurochir (Wien) 147:367–375CrossRef Nicolato A, Giorgetti P, Foroni R, Grigolato D, Pasquin IP, Zuffante M et al (2005) Gamma knife radiosurgery in skull base meningiomas: a possible relationship between somatostatin receptor decrease and early neurological improvement without tumour shrinkage at short-term imaging follow-up. Acta Neurochir (Wien) 147:367–375CrossRef
16.
go back to reference Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S et al (1998) Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 39:1913–1917PubMed Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S et al (1998) Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 39:1913–1917PubMed
17.
go back to reference Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R et al (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865–1874PubMed Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R et al (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865–1874PubMed
18.
go back to reference Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836–846PubMedCrossRef Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836–846PubMedCrossRef
19.
go back to reference Schulz S, Helmholz T, Schmitt J, Franke K, Otto HJ, Weise W (2002) The positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of ss2A and sst5. Breast Cancer Res Treat 72:221–226PubMedCrossRef Schulz S, Helmholz T, Schmitt J, Franke K, Otto HJ, Weise W (2002) The positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of ss2A and sst5. Breast Cancer Res Treat 72:221–226PubMedCrossRef
20.
21.
go back to reference Mezi S, Primi F, Orsi E, Capoccetti F, Scopinaro F, Schillaci O (2005) Somatosatin scintigraphy in the metastatic breast cancer patients. Oncol Rep 13:31–35PubMed Mezi S, Primi F, Orsi E, Capoccetti F, Scopinaro F, Schillaci O (2005) Somatosatin scintigraphy in the metastatic breast cancer patients. Oncol Rep 13:31–35PubMed
22.
go back to reference Nathoo N, Ugokwe K, Chang AS, Li L, Ross J, Suh JH et al (2007) The role of 111 indium–octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neuro-Oncol 81:167–174CrossRef Nathoo N, Ugokwe K, Chang AS, Li L, Ross J, Suh JH et al (2007) The role of 111 indium–octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neuro-Oncol 81:167–174CrossRef
23.
go back to reference Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, Virgolinin I (2005) Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med 32:1440–1451CrossRef Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, Virgolinin I (2005) Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med 32:1440–1451CrossRef
24.
go back to reference Hasseleid BF, Meling TR, Rønning P, Scheie D, Helseth E (2012) Surgery for convexity meningioma: Simpson grade I resection as the goal: clinical article. J Neurosurg 117(6):999–1006PubMedCrossRef Hasseleid BF, Meling TR, Rønning P, Scheie D, Helseth E (2012) Surgery for convexity meningioma: Simpson grade I resection as the goal: clinical article. J Neurosurg 117(6):999–1006PubMedCrossRef
25.
go back to reference Willis J, Smith C, Ironside J, Erridge S, Whittle I, Everington D (2005) The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 31:141–149PubMedCrossRef Willis J, Smith C, Ironside J, Erridge S, Whittle I, Everington D (2005) The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 31:141–149PubMedCrossRef
26.
go back to reference Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182PubMedCrossRef Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182PubMedCrossRef
27.
go back to reference Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M et al (2009) Correlation of immunohistopathological expression of somatostatin receptor-2 with standardized uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med 36:48–52CrossRef Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M et al (2009) Correlation of immunohistopathological expression of somatostatin receptor-2 with standardized uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med 36:48–52CrossRef
Metadata
Title
Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma
Authors
Shengjun Wang
Weidong Yang
Jinglan Deng
Jianning Zhang
Fucheng Ma
Jing Wang
Publication date
01-07-2013
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2013
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1146-y

Other articles of this Issue 3/2013

Journal of Neuro-Oncology 3/2013 Go to the issue